source
- TRexBio and Retension raise $161.7M in IPOs as biotech fundraising surge continuesTRexBio and Retension Pharmaceuticals are slated to begin trading on Friday, together raising $161.7 million. Their offerings push the number of biotech IPOs this year to 29, underscoring a continu…
- TRex Bio prices $117M IPO to fund Treg-targeted immune therapiesTRex Bio announced pricing of its initial public offering at $117 million, selling 8,333,334 shares at $14 each, meeting the low end of its earlier guidance. The company will begin trading on Nasd…